Noxopharm has completed putting in place the required logistics to enable it to conduct a clinical study of its lead pipeline drug candidate, NOX66, in Europe, commencing before the end of 2016.
The study is designed as a progressive Phase 1a/Phase 1b and prospective Phase 2a and is being conducted at two clinical sites in Tbilisi, Georgia. Georgia has been selected because of the speed with which the study can be recruited, and therefore completed.
UK-based contract research organisation (CRO), Clinical Accelerator, has been appointed to manage the study. Clinical Accelerator specialises in clinical trials management in Central and Eastern Europe.
Data management and statistics will be conducted by Australian CRO, Datapharm Australia Pty Ltd.
A Sydney-based oncologist will act as senior Medical Monitor.
Overall management is in the hands of Dr Marinella Messina, Noxopharm Clinical Affairs Manager.
For further information please download PDF attached:
Download this document
